Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants

18 May 2021

Abstract excerpt

Due to their increased transmissibility, three variants of high concern have emerged in the United Kingdom (also known as B.1.1.7 lineage or VOC-202012/01), South Africa (B.1.351 lineage), and Brazil (P1 lineage) with multiple substitutions in the spike protein. Since neutralizing antibodies elicited by vaccination are likely considered as correlates of protection for SARS-CoV-2 infection, it is important to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral Infections and Immunology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34069852
DOI: 10.3390/vaccines9050517

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 VariantsPMID 34069852Read ↗

Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2Semantic proximity Read ↗

Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera.Semantic proximity Read ↗

BNT162b2 Vaccination in People Over 80 Years of Age Induces Strong Humoral Immune Responses with Cross Neutralisation of P.1 Brazilian VariantSemantic proximity Read ↗

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human seraSemantic proximity Read ↗

Neutralizing antibodies to SARS‐CoV‐2 variants of concern including Delta and Omicron in subjects receiving mRNA‐1273, BNT162b2, and Ad26.COV2.S vaccinesSemantic proximity Read ↗

COVID-19 mRNA vaccine induced antibody responses and neutralizing antibodies against three SARS-CoV-2 variantsSemantic proximity Read ↗

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human seraSemantic proximity Read ↗

Previously infected vaccinees broadly neutralize SARS-CoV-2 variantsSemantic proximity Read ↗

Neutralization of SARS-CoV-2 Omicron pseudovirus by BNT162b2 vaccine-elicited human seraSemantic proximity Read ↗

Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients.Semantic proximity Read ↗

SARS-CoV-2 B.1.1.7 escape from mRNA vaccine-elicited neutralizing antibodiesSemantic proximity Read ↗

Functional and quantitative evaluation of BNT162b2 SARS-CoV-2 vaccine-induced immunitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.